ImpediMed’s SOZO® Digital Health Platform Captures First Place in 19th Innovations in Healthcare™ ABBY Award

Richard Carreon, managing director and CEO accepts prestigious honor.

Brisbane, Australia and Carlsbad, CA – December xx, 2018 – ImpediMed Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that its SOZO® Digital Health Platform was awarded the top distinction in a competitive field of ABBY-nominated semi-finalists at the ABL Organization’s 19th Innovations in Healthcare ABBY Awards in the category of Innovative Health IT or Digital Health Technology. SOZO is a leading, non-invasive and FDA-cleared BIS digital health platform that measures, monitors and manages fluid accumulation in patients with certain conditions resulting from cancer treatment, such as lymphedema (LE) and heart failure (HF).

Richard Carreon, managing director and CEO, ImpediMed, accepted the award from the Finalist Selection Committee, a group of healthcare executives with deep domain knowledge in the areas represented by this year’s semi-finalists. The committee reviewed and discussed the semi-finalist companies, and voted by secret ballot to select the finalist.

ImpediMed joins a distinguished group of previous ABBY Award Winners that includes numerous companies that have made breakthroughs and transformative advances in medical devices, diagnostics, therapeutics, information technology, and electronic solutions. These companies and organizations have applied innovative systems and technology to providing care and coverage, decreasing the numbers of uninsured, and engaging healthcare consumers more actively in their care and health status - all with a view to reducing the cost of quality care.
“We are truly honored that SOZO is being recognized as breakthrough technology to enhance cancer survivorship,” says Carreon. “This is game-changing technology as L-Dex detects the onset of lymphedema very early and has been clinically proven to detect subclinical lymphedema up to 10 months before any visible symptoms. If detected at stage 0 or stage 1, the progression of lymphedema can be prevented, and often reversed. Numerous clinical trials have shown a 75% to 95% reduction in persistent, clinical lymphedema.”

About ImpediMed

Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications, including heart failure and lymphedema, sold in select markets globally. Visit www.impedimed.com.